News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Celldex Touts Brain Cancer Vaccine Data, Talks FDA Strategy

Al's Comment:

 Celldex presented impressive data at the SNO meeting last week.  They had a 3.4 month survival advantage with recurrent GBM patients.  That should be a large enough benefit to get FDA approval. They will wait until they have the results on more patients, and if it hold up to this level of benefit, will ask FDA for approval.  This would be a tremendous benefit as it is a simple vaccine with minimal side effects.

Posted on: 11/17/2014


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557